DUBLIN, Jan. 23, 2017 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced its continued support of the International Headache Academy (IHA). Designed to inspire a long-term commitment to Headache Medicine in young neurologists and research scientists, IHA offers a three-day, intensive overview on research and treatment options. This is the fourth year that Allergan has been the sole sponsor since the inception of IHA in North America in 2013, and iHEAD in Europe in 2014.
“Allergan is dedicated to improving the lives of those affected by headache disorders. Beyond advancing research and treatment options, we share a similar goal with IHA – to raise the level of education among headache experts and improve patient care,” said David Nicholson, Chief R&D Officer at Allergan. “The more knowledge and support neurologists have, the better equipped they will be to help patients make critical decisions about their health.”
The recent 2017 IHA at the UCLA Meyer & Renee Luskin Conference Center in Los Angeles, CA offered a highly interactive educational program including future research priorities, validating potential drug targets, emerging new treatments, and the importance of patient advocacy.
“IHA is committed to developing and nurturing future leaders in headache medicine,” said Dr. David Dodick, Chair of the American Migraine Foundation and President of the International Headache Society. “We are inspired by our attendees’ commitment to raising their level of education and improving patient care and are grateful to Allergan for their involvement.”
Allergan, a leader in the Chronic Migraine space, has offered Botox® (onabotulinumtoxinA) the first and only FDA-approved, preventive treatment for adult Chronic Migraine patients since it was approved in 2010. Allergan is advancing its migraine program with two investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine. Allergan’s CGRPs, ubrogepant in Phase III for the acute treatment of migraine and atogepant in Phase II for the prevention of migraine, are expected to be the first oral CGRP receptor antagonists to market.
For more career advice and breaking medical news and jobs in the medical field visit Med Career News today.